Recipharm receives approval for the manufacture of a new microbiome-based therapeutic
Recipharm receives regulatory approval for the manufacture of a microbiome-based product for the prevention of Clostridioides difficile recurrent infection, under GenIbet Biopharmaceuticals and Seres Therapeutics.
The leading CDMO in biopharmaceuticals Recipharm has received approval from the US FDA for its auxiliary partner GenIbet Biopharmaceuticals to manufacture its orally-administered fecal microbiota product, VOWST.
VOWST is used to prevent Clostridioides difficile recurrent infection (CDI) in adults who have already received antibacterial treatment for the infection. CDI is one of the biggest microbial health risks in the USA according to the Centers for Disease Control and Prevention, responsible for around 30,000 deaths each year.
Recipharm will oversee the manufacturing of the microbiota product at the GenIbet site in Oeiras, Portugal, in tandem with Seres Therapeutics.
Raquel Fortunato, CEO of GenIbet, commented:
“FDA’s approval is a major development in the biologics market. It will help shift the perception of microbiome medicines and open the door for new opportunities for patients around the world.
I would like to thank colleagues, past and present, who have been involved in the VOWST project. Their hard work and perseverance over almost ten years have enabled this major milestone which has the potential to improve patients’ health and save lives. I can’t think of a better example to illustrate our mission, to be the bridge between innovators and patients.”
Under Recipharm, GenIbet Biopharmaceuticals is experienced in manufacturing of biological clinical trial material, viral vectors, RNA, and microbiome therapeutics in particular. In 2014 GenIbet began supporting Seres Therapeutics, specialising in clinical trial supply, process validation, and BLA submission, from there they progressed to enabling the VOWST Tech Transfer and taking over the GMP manufacturing of the product.
GenIbet Biopharmaceuticals is known for developing novel production processes in the preclinical and Phase I and II clinical trial stages.
The recent FDA approval will mean that Recipharm can expand its manufacturing capabilities and increase the output of novel modalities for manufacturing biologics.
Related News
-
News Pharma CEOs write open letter calling suppliers to commit to sustainability
Several big pharma companies have added their names to a letter challenging suppliers in the healthcare industry to pledge to sustainability targets. -
News Alzheimer's drug donanemab deemed effective in landmark clinical trial
Results from the TRAILBLAZER-ALZ 2 Randomised Clinical Trial into the use of donanemab to treat early symptoms of Alzheimer’s disease have been analysed. -
News Ardena forms partnership with RiboPro to improve mRNA-based therapies
Ardena and RiboPro have formed an alliance to boost their respective skills in manufacturing and producing nanoparticle and mRNA-based therapeutics to improve accessibility to this technology in the biotherapeutic landscape. -
News Humira biosimilars at discounted prices to meet market demand for accessible treatment
Several biosimilars to AbbVie’s monoclonal antibody therapeutic Humira were launched by various pharmaceutical giants this week in the US, with more expected to be released by the end of the year as the patent expires. -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News Women in Pharma: Gearing up for systemic change
In our new monthly series, we interview women from across the pharmaceutical industry and supply chain to discuss the importance of gender diversity in healthcare, the workplace, and beyond. -
News Delivering on mRNA-based therapeutics: innovations in applications and packaging
Since the onset of the COVID-19 pandemic, the innovative potential of mRNA vaccines and therapeutics has raised questions regarding their manufacturing, packaging, and storage/transportation. Learn about how the pharmaceutical supply chain is meet... -
News Your Prescription for Marketing Success: Digital Pharma Marketing Toolkit – Free eBook
Download your FREE pharma marketing eBook to learn why it is so important for pharmaceutical marketeers to develop their digital content marketing strategies in order to establish their companies as thought leaders and industry experts.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance